AA
IDXG

Ancora Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Ancora Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,479
Closed -$13K – 687
2017
Q2 		$13K Hold
1,479
– – ﹤0.01% 624
2017
Q1 		$39K Hold
1,479
– – ﹤0.01% 615
2016
Q4 		$65K Sell
1,479
-1,100
-43% -$35.1K ﹤0.01% 735
2016
Q3 		$41K Hold
2,579
– – ﹤0.01% 521
2016
Q2 		$85K Hold
2,579
– – 0.01% 499
2016
Q1 		$72K Hold
2,579
– – 0.01% 481
2015
Q4 		$120K Sell
2,579
-450
-15% -$50.1K 0.02% 470
2015
Q3 		$542K Hold
3,029
– – 0.07% 291
2015
Q2 		$433K Buy
+3,029
New +$420K 0.05% 344
2015
Q1 		– Sell
-1,550
Closed -$254K – 382
2014
Q4 		$277K Buy
+1,550
New +$276K 0.03% 406

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Ancora Advisors's IDXG Position: Q3 2017 in Review

Ancora Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2017, closing a stake of 1,479 shares — an estimated $13K sold.

Ancora Advisors first reported a position in IDXG in Q4 2014 and held it in 10 quarters. The position peaked at $542K in Q3 2015. 13 funds tracked by Wall St. Rank hold IDXG as of Q3 2017.

  • Ancora Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Ancora Advisors sold 1,479 Interpace Biosciences, Inc. Common Stock shares in Q3 2017, an estimated $13K.
  • Ancora Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
  • Ancora Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $542K in Q3 2015.
  • 13 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2017.

Based on Ancora Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.